Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the drug market for type 2 diabetes will reach $20.5 billion in 2012, representing a robust 2002-2012 annual growth rate of 8%. According to the new Pharmacor report entitled Type 2 Diabetes, driving the expansion of this market are emerging agents that offer novel mechanisms of action, such as the glucagon-like peptide-1 (GLP-1) analogues, and improvements on existing therapies, such as inhaled insulin and dual-acting peroxisome proliferator-activated receptor (PPAR) agonists.

"Between 2006 and 2012, dual-acting PPAR agonists and GLP-1 analogues will capture significant shares of the type 2 diabetes market," said Carole Gleeson, analyst at Decision Resources. "Many physicians consider dual-acting PPAR agonists and inhaled insulin to be promising agents, but they are concerned about safety issues and await more clinical trial data. The experts also recognize the potential of GLP-1 analogues, which will be strong competitors to existing insulin secretagogues."

About Type 2 Diabetes

The International Diabetes Foundation recently warned that type 2 diabetes had become a global pandemic and one of the most challenging public health problems of the 21st century. It is a progressive disease of metabolic deregulation characterized by insulin resistance and impaired insulin secretion. Prevalence of this complex disease soared in the United States in the past decade and is expected to increase rapidly in the near future. The enormous size of the patient population and the limitations of existing therapies in reducing severe complications and altering disease progression represent vast, untapped commercial opportunity.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Type 2 Diabetes is a Metabolic Disorders study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Insurance Companies Refuse to Reimburse Weight-Loss Treatments Citing Lack of Efficacy Data

View Now